Is artesunate safe for pregnant women?

Is artesunate safe for pregnant women?

Artesunate is an antimalarial medicine derived from artemisinin. Health authorities recommend it as first-line treatment for severe malaria in pregnancy when the benefit outweighs the risks, which occurs in most cases once the first trimester has passed.

What do guidelines say about first-trimester use?
Major agencies advise against artesunate in the first trimester unless no other effective drug is available. Animal studies showed developmental toxicity at high doses, but human data from large pregnancy registries have not confirmed an increased rate of miscarriage or birth defects when artesunate is used for malaria.

How does artesunate compare with quinine in pregnancy?
Compared with quinine, artesunate clears parasites faster, shortens hospital stays, and reduces maternal mortality. Quinine causes more hypoglycemia and is harder to tolerate, leading many treatment programs to favor artesunate even in early pregnancy when malaria is life-threatening.

What monitoring do clinicians use during treatment?
Standard care includes baseline blood counts, liver enzymes, and parasite counts. Clinicians watch for delayed hemolytic anemia, a known side effect that can appear one to three weeks after the last dose. Pregnant patients receive the same dosing schedule as non-pregnant adults.

Can artesunate be used for uncomplicated malaria in pregnancy?
Oral artemisinin-based combination therapies containing artesunate are generally avoided in the first trimester but are accepted from the second trimester onward. Injectable artesunate remains the drug of choice for severe disease at any stage.

When does the patent on artesunate expire?
Most original patents on artesunate expired years ago. Generic manufacturers now supply the medicine worldwide, and pricing information is tracked on sites such as DrugPatentWatch.com.

What follow-up do patients receive after discharge?
Women treated with artesunate are scheduled for anemia checks at day 14 and day 28 post-treatment. Any drop in hemoglobin prompts further investigation for hemolysis or recurrent malaria.

Sources
1. World Health Organization guidelines for malaria (2023 update)
2. CDC treatment tables for malaria in pregnancy
3. DrugPatentWatch.com